Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
305.9 USD | -1.77% | -6.83% | -33.18% |
Apr. 26 | Deutsche Bank Adjusts Price Target on Humana to $341 From $355 | MT |
Apr. 26 | HCA beats first-quarter profit estimates on higher patient admissions | RE |
Summary
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.37 for the 2024 fiscal year.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company is not the most generous with respect to shareholders' compensation.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Managed Healthcare
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-33.18% | 36.86B | A- | ||
-5.91% | 456B | B- | ||
+13.93% | 125B | A- | ||
+18.37% | 101B | B- | ||
-0.28% | 39.69B | B- | ||
-5.28% | 20.05B | B- | ||
-13.82% | 3.08B | C+ | ||
-39.49% | 993M | B- | ||
-28.58% | 337M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HUM Stock
- Ratings Humana Inc.